Insurance companies continue to deny complex medical equipment for patients whom it is medically necessary. The rules keep changing. It can be difficult to keep up with the latest equipment […]
We’re thrilled to share news about Code Biotherapeutics, a company pioneering targeted non-viral delivery of genetic medicines. CureDuchenne’s April 2021 research investment into Code Biotherapeutics was based on extensive preclinical […]
CureDuchenne joins forces with NIH, FDA, and private organizations to increase effective gene therapies for rare diseases CureDuchenne is delighted to be a partner in the Accelerating Medicines Partnership Bespoke […]
In WMS 2021’s final day and “late-breaking news” session, Capricor Therapeutics announced positive final data from its Phase 2 HOPE-2 clinical trial in Duchenne patients treated with CAP-1002. HOPE-2 was […]
WMS 2021 on Thursday, September 23rd was a full day of oral and poster presentations, and we’ll highlight some Duchenne clinical trial updates covered. Solid Biosciences – SGT-001 micro-dystrophin gene […]
WMS 2021’s agenda on Wednesday, September 22nd was not so much about specific diseases, but rather major and timely research themes across all of biology. The day started with a […]
Monday, September 20th was the first day of the WMS 2021 Virtual Congress, and a day devoted to symposia sponsored by various companies developing therapeutic treatments for neuromuscular disorders. Most […]
It’s that time of year again, when neuromuscular disease researchers clear their calendars for the Annual International Congress of the World Muscle Society (WMS), the largest conference focused solely on […]
CureDuchenne Cares Advocacy Efforts Succeed in Adding Duchenne to the Social Security Administration Compassionate Allowance List (CAL) Social Security Disability Insurance (SSDI) benefits are a financial lifeline for millions of […]
